Inhibition of IGF2BP1 can reduce the stability of PKCα mRNA, the expression of PKCα protein, and MAPK/ERK activation to improve overall survival in melanoma (Mahapatra et al., 2019). The gene discussed is PRKCA; the disease is melanoma.